image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates. 

V1A receptor

Family: Vasopressin and oxytocin receptors

Contents:
Gene and Protein Information
Previous and Unofficial Names
Database Links
Agonists
Antagonists
Transduction Mechanisms
Tissue Distribution
Expression Datasets
Functional Assays
Physiological Functions
Physiological Consequences of Altering Gene Expression
Phenotypes, Alleles and Disease Models
Biologically Significant Variants
General Comments
References
Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 418 12q14-q15 AVPR1A arginine vasopressin receptor 1A 70-71
Mouse 7 423 10 D3 Avpr1a arginine vasopressin receptor 1A 34
Rat 7 424 7q21 Avpr1a arginine vasopressin receptor 1A 42
Previous and Unofficial Names
V1
V1aR
arginine vasopressin receptor 1A
AVPR1
AVPR
MGC108538
V1a
Vasopressin receptor V1a
antidiuretic hormone receptor 1a
arginine vasopressin receptor V1a
vascular/hepatic-type arginine vasopressin receptor
vasopressin V1a receptor
Database Links
ChEMBL Target 134 (Hs), 11680 (Rn)
DrugBank Target 185 (Hs)
Ensembl ENSG00000166148 (Hs), ENSMUSG00000020123 (Mm), ENSRNOG00000004400 (Rn)
Entrez Gene 552 (Hs), 54140 (Mm), 25107 (Rn)
GeneCards AVPR1A (Hs)
GenitoUrinary Development Molecular Anatomy Project Avpr1a (Mm)
HomoloGene 568 (Hs)
Human Protein Reference Database 02894 (Hs)
InterPro P37288 (Hs), Q62463 (Mm), P30560 (Rn)
KEGG Gene hsa:552 (Hs), mmu:54140 (Mm), rno:25107 (Rn)
OMIM 600821 (Hs)
PharmGKB Gene PA25187 (Hs)
PhosphoSitePlus P37288 (Hs), Q62463 (Mm), P30560 (Rn)
Protein Ontology (PRO) PRO:000001681 (Hs)
RefSeq Nucleotide NM_000706 (Hs), NM_016847 (Mm), NM_053019 (Rn)
RefSeq Protein NP_000697 (Hs), NP_058543 (Mm), NP_444178 (Rn)
TreeFam ENSG00000166148 (Hs), ENSMUSG00000020123 (Mm), ENSRNOG00000004400 (Rn)
UniGene Hs. 2131 (Hs)
UniProt P37288 (Hs), Q62463 (Mm), P30560 (Rn)
Wikipedia V1A receptor
Vasopressin and oxytocin receptors
Search for 3D structures on the PDB
Search by keyword: Vasopressin and oxytocin receptors V1A receptor Search by accession number: P30560, P37288, Q62463
Natural/Endogenous Ligand(s)
oxytocin {Sp: Human, Mouse, Rat}
vasopressin {Sp: Human, Mouse, Rat}
Comments: vasopressin is the principal endogenous agonist
Rank order of potency (Human)
AVP > oxytocin
Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[3H]AVP Hs Full agonist 8.6 – 10.2 pKd 9,16,19-20,46,51,53,62-63,70,72,75,78
F180 Hs Full agonist 7.9 – 8.3 pKd 2,19
[3H]OT (human, mouse, rat) Hs Full agonist 6.9 pKd 51
d[D-Phe2]AVP Hs Full agonist 9.2 pKi 21
vasopressin {Sp: Human, Mouse, Rat} Hs Full agonist 8.5 – 9.3 pKi 1,15,19,21,46,51,53,62-63,70,72,78
LVP {Sp: Pig} Hs Full agonist 8.6 pKi 72
AVT Rn Full agonist 8.5 pKi 16
dAVP Hs Full agonist 8.4 pKi 15,21
vasopressin {Sp: Human, Mouse, Rat} Rn Full agonist 8.4 pKi 16
AVT Hs Full agonist 8.3 pKi 72
[Phe2]OVT Hs Full agonist 8.3 pKi 51
dVDAVP Hs Full agonist 7.6 – 8.0 pKi 21,72
oxytocin {Sp: Human, Mouse, Rat} Hs Full agonist 6.9 – 8.3 pKi 1,17,51,53,62-63,70,72
d[D-Pal2]AVP Hs Full agonist 7.5 pKi 15,21
[Val4]AVP Hs Full agonist 7.5 pKi 21
d[Leu4]AVP Hs Full agonist 7.4 pKi 15
desmopressin Hs Full agonist 7.0 – 7.7 pKi 15,46,51,53,62,72
d[Cha4]AVP Hs Full agonist 7.1 pKi 21
[Thr4,Gly7]OT Hs Full agonist 6.5 – 6.8 pKi 51,62
[Phe3]OT Rn Full agonist 6.3 pKi 16
DAVP Rn Full agonist 6.1 pKi 16
OPC-51803 Hs Full agonist 6.1 pKi 46
oxytocin {Sp: Human, Mouse, Rat} Rn Full agonist 6.1 pKi 16
desmopressin Rn Full agonist 5.6 pKi 16
d[Leu4,Dap8]VP Rn Full agonist 5.5 pKi 50
d[Cha4,Dab8]VP Rn Full agonist 5.4 pKi 50
d[Leu4]LVP Rn Full agonist 5.4 pKi 50
d[Cha4]LVP Rn Full agonist 5.0 pKi 50
View species-specific agonist tables
Agonist Comments
The binding affinities at the V1A receptor found in study [50] are from native tissues.
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[125I]OH-LVA Hs Antagonist 10.3 – 10.4 pKd 16,19,51
[125I]3-N3-Phpa-LVA Hs Antagonist 9.9 pKd 51
d(CH2)5[Tyr(Me)2,Thr4,Phe(3125I,4N3)-NH29]OVT Hs Antagonist 9.3 pKd 9
d(CH2)5[Tyr(Me)2,Thr4,Tyr(3125I)-NH29]OVT Hs Antagonist 9.0 pKd 9
3-N3-Phpa-LVA Hs Antagonist 9.6 pKi 51
YM 218 Hs Antagonist 9.5 pKi 66
OH-LVA Hs Antagonist 9.3 pKi 72
[Phaa1,D-Tyr2,Val4,Arg6,Arg-NH29]AVP Hs Antagonist 9.2 pKi 72
YM 471 Hs Antagonist 9.2 pKi 75
d(CH2)5[D-Tyr(Et)2,Val4,Tyr-NH29]AVP Hs Antagonist 9.1 pKi 19
d(CH2)5[Tyr(Et)2,Val4,des-Gly9]AVP Hs Antagonist 9.1 pKi 62
d[Pen1,Tyr(Me)2]AVP Hs Antagonist 9.1 pKi 62
[Phaa1,D-Tyr(Me)2,Arg6,Tyr-NH29]AVP Hs Antagonist 9.1 pKi 72
[tBaa1,D-Tyr(Et)2,Val4,Lys6,Arg-NH28,des-Gly9]AVP Hs Antagonist 9.1 pKi 72
[Phaa1,D-Tyr(Et)2,Lys6,des-Gly9]AVP Hs Antagonist 8.9 – 9.1 pKi 70,72
d(CH2)5[Tyr(Me)2,Thr4,Phe(3I,4N3)-NH29]OVT Hs Antagonist 8.9 pKi 9
d(CH2)5[Tyr(Me)2]AVP Hs Antagonist 8.4 – 9.2 pKi 19,51,53,62-63,72
SR 49059 Hs Antagonist 8.1 – 9.3 pKi 1,19,26,51,55,62,70,72,75
[Phaa1,D-Tyr(Et)2,Val4,Lys6,Tyr-NH28,des-Gly9]AVP Hs Antagonist 8.5 – 8.6 pKi 70,72
atosiban Hs Antagonist 8.3 – 8.5 pKi 1,17,40,56
d[D-Pal2]AVP Hs Antagonist 8.4 pKi 72
d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH29]OVT Hs Antagonist 8.3 – 8.4 pKi 40,72
conivaptan Hs Antagonist 8.2 – 8.4 pKi 62-63
d(CH2)5[Tyr(Me)2,Thr4]OVT Hs Antagonist 8.1 pKi 72
tolvaptan Hs Antagonist 7.9 pKi 78
RWJ-351647 Hs Antagonist 7.6 pKi 28
d(CH2)5[D-Ile2,Ile4,Ala-NH29]AVP Hs Antagonist 7.5 pKi 72
L023103 Hs Antagonist 7.4 pKi 52
d(CH2)5[D-Ile2,Ile4,Ala-NH2]AVP Hs Antagonist 7.2 – 7.3 pKi 70,72
SSR149415 Hs Antagonist 7.0 pKi 58
OPC-31260 Hs Antagonist 6.8 – 7.1 pKi 62,72,78
SSR126768A Hs Antagonist 6.8 pKi 56
LS-192629 Hs Antagonist 6.7 pKi 17
SR 121463A Hs Antagonist 6.5 pKi 62,75
tolvaptan Rn Antagonist 6.5 pKi 78
OPC-31260 Rn Antagonist 6.3 pKi 78
OPC-21268 Hs Antagonist 5.1 pKi 72
View species-specific antagonist tables

Explore drug-target interactions for this set of compounds using iPHACE

Primary Transduction Mechanisms
Transducer Effector/Response
Gq/G11 family Phospholipase C stimulation
References:  54
Tissue Distribution
Adrenal gland (medulla and cortex).
Species:  Human
Technique:  RT-PCR.
References:  25,27
Myometrium.
Species:  Human
Technique:  in situ hybridisation.
References:  73
Platelets.
Species:  Human
Technique:  RT-PCR.
References:  29
Liver > heart, kidney, skeletal muscle.
Species:  Human
Technique:  Northern blotting.
References:  71
Cardiomyocytes.
Species:  Rat
Technique:  RT-PCR.
References:  13
Kidney: glomerulus, initial cortical collecting duct, cortical collecting duct, outer medullary collecting duct, inner medullary collecting duct, arcuate artery > proximal convoluted and straight tubules, inner medullary thin limbs, medullary thick ascending limbs.
Species:  Rat
Technique:  RT-PCR.
References:  67
Uterus.
Species:  Rat
Technique:  RT-PCR.
References:  18
CNS: frontal cortex, piriform cortex, internal granular layer and the medial, dorsal, ventral and lateral portion of the anterior olfactory nucleus, zona limitans of the islands of Calleja, suprachiasmatic nucleus, CA1, CA2, CA3 and dentate gyrus of the hippocampus, paraventricular hypothalamic nucleus, ventromedial hypothalamic nucleus, arcuate nucleus, lateral habenular nucleus, molecular and granular cell layers of the cerebellum.
Species:  Rat
Technique:  in situ hybridisation.
References:  48,60
Lung.
Species:  Rat
Technique:  Radioligand binding.
References:  65
Testis.
Species:  Rat
Technique:  Radioligand binding.
References:  41
Liver.
Species:  Rat
Technique:  in situ hybridisation.
References:  49
Vascular smooth muscle cells.
Species:  Rat
Technique:  Northern blotting.
References:  44
Adrenal gland.
Species:  Rat
Technique:  RT-PCR.
References:  27,74
Kidney.
Species:  Rat
Technique:  in situ hybridisation.
References:  49
Adult: brain, lung, liver, kidney.
Newborn: brain, liver, heart, kidney.
Species:  Rat
Technique:  RT-PCR.
References:  30
Expression Datasets

Click here to show/hide data

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of inositol phosphate accumulation in CHO cells transfected with the human V1A receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Stimulation of IP accumulation.
References:  70
Measurement of inositol phosphate accumulation in COS-7 cells transfected with the human V1A receptor.
Species:  Human
Tissue:  COS-7 cells.
Response measured:  Stimulation of IP accumulation.
References:  70
Measurement of calcium levels in CHO cells transfected with the rat V1A receptor.
Species:  Rat
Tissue:  CHO cells.
Response measured:  Stimulation of calcium mobilisation.
References:  10
Measurement of arachidonic acid levels in CHO cells transfected with the rat V1A receptor.
Species:  Rat
Tissue:  CHO cells.
Response measured:  Stimulation arachidonic acid release.
References:  10
Measurement of calcium levels in CHO cells transfected with the human V1A receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Stimulation of calcium mobilisation.
References:  62
Measurement of MAP kinase activation in CHO cells transfected with the human V1A receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Stimulation of MAP kinase activation.
References:  64
Physiological Functions
Myometrial contraction.
Species:  Human
Tissue:  Myometrial strips.
References:  73
Vasoconstriction.
Species:  Rat
Tissue:  Isolated uterine resistance arteries.
References:  14
Vasoconstriction.
Species:  Rat
Tissue:  Isolated perfused kidney.
References:  39
Vasoconstriction.
Species:  Rat
Tissue:  Isolated mesenteric artery rings.
References:  59
Vasoconstriction.
Species:  Human
Tissue:  In vivo.
References:  11
Hypertension.
Species:  Rat
Tissue:  In vivo.
References:  45,61
Tissue regeneration.
Species:  Rat
Tissue:  Adrenal gland.
References:  74
Aldosterone and corticosterone secretion.
Species:  Rat
Tissue:  Adrenal gland.
References:  24
Platelet aggregation.
Species:  Human
Tissue:  Platelets.
References:  29,57
Glucose homeostasis.
Species:  Mouse
Tissue:  In vivo.
References:  3
Regulation of heart rate.
Species:  Mouse
Tissue:  In vivo.
References:  47
Cardiomyocyte hypertrophy.
Species:  Mouse
Tissue:  Isolated cardiomyocytes.
References:  33
Physiological Consequences of Altering Gene Expression
V1A receptor knockout mice exhibit altered reflex changes in heart rate.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  47
V1A receptor knockout mice exhibit a decrease in blood pressure and circulating blood volume.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  37
V1A receptor knockout mice exhibit altered lipid metabolism.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  31
V1A receptor knockout mice exhibit altered glucose homeostasis.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  3
V1A receptor knockout mice exhibit attenuated cardiac hypertrophy in response to pressure overload.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  33
Male V1A receptor knockout mice exhibit a decrease in anxiety-like behaviour and impaired social recognition. No such effects were observed in female V1A knockout mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  5,7
Re-expressing the V1A receptor in the lateral septum of V1A receptor knockout mice restores impaired social memory; mice overexpressing the V1A receptor exhibit potentiation of social recognition and a slight increase in anxiety-related behaviour.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells; viral gene transfer.
References:  6
V1A receptor knockout mice exhibit impaired spacial memory.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  22
V1A receptor knockout mice exhibit a decrease in anxiety-like behaviour and impaired social recognition. This effect was seen in both male and female receptor knockout mice suggesting that there is no sexual dimorphism involved.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  23
V1A receptor knockout mice exhibit enhanced proteolysis and gluconeogenesis.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  32
V1A receptor (and V1B receptor) knockout mice exhibit normal, acute intoxicating behavioural effects following ethanol ingestion.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  12
V1A receptor knockout mice exhibit impaired aldosterone secretion.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  8
V1A receptor knockout mice exhibit subtle olfactory deficit but normal aggression.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  77
Phenotypes, Alleles and Disease Models Mouse data from MGI

Click here to show/hide data

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Avpr1atm1Gzt Avpr1atm1Gzt/Avpr1atm1Gzt
involves: 129/Sv * C57BL/6J		 MGI:1859216  MP:0000639 abnormal adrenal gland morphology PMID: 16682631 
Avpr1atm1Gzt Avpr1atm1Gzt/Avpr1atm1Gzt
involves: 129/Sv * C57BL/6J		 MGI:1859216  MP:0004184 abnormal baroreceptor physiology PMID: 16682631 
Avpr1atm1Sbhu Avpr1atm1Sbhu/Avpr1atm1Sbhu
involves: C57BL/6		 MGI:1859216  MP:0002144 abnormal B cell differentiation PMID: 12576226 
Avpr1atm1Gzt Avpr1atm1Gzt/Avpr1atm1Gzt
involves: 129/Sv * C57BL/6J		 MGI:1859216  MP:0005345 abnormal circulating corticosterone level PMID: 16682631 
Avpr1atm1Gzt Avpr1atm1Gzt/Avpr1atm1Gzt
involves: 129/Sv * C57BL/6J		 MGI:1859216  MP:0001629 abnormal heart rate PMID: 16682631 
Avpr1atm1Sbhu Avpr1atm1Sbhu/Avpr1atm1Sbhu
involves: C57BL/6		 MGI:1859216  MP:0002490 abnormal immunoglobulin level PMID: 12576226 
Avpr1atm1Gzt Avpr1atm1Gzt/Avpr1atm1Gzt
involves: C57BL/6		 MGI:1859216  MP:0001449 abnormal learning/ memory PMID: 15036628 
Avpr1atm1Sbhu Avpr1atm1Sbhu/Avpr1atm1Sbhu
129X1.Cg-Avpr1a		 MGI:1859216  MP:0001360 abnormal social investigation PMID: 14647484 
Avpr1atm1Gzt Avpr1atm1Gzt/Avpr1atm1Gzt
involves: 129/Sv * C57BL/6J		 MGI:1859216  MP:0000250 abnormal vasoconstriction PMID: 16682631 
Avpr1atm1Sbhu Avpr1atm1Sbhu/Avpr1atm1Sbhu
129X1.Cg-Avpr1a		 MGI:1859216  MP:0001364 decreased anxiety-related response PMID: 14647484  16046007 
Avpr1atm1Gzt Avpr1atm1Gzt/Avpr1atm1Gzt
involves: 129/Sv * C57BL/6J		 MGI:1859216  MP:0005523 decreased circulating atrial natriuretic factor PMID: 16682631 
Avpr1atm1Sbhu Avpr1atm1Sbhu/Avpr1atm1Sbhu
involves: C57BL/6		 MGI:1859216  MP:0008497 decreased IgG2b level PMID: 12576226 
Avpr1atm1Dgen Avpr1atm1Dgen/Avpr1atm1Dgen
involves: 129P2/OlaHsd * C57BL/6		 MGI:1859216  MP:0009142 decreased prepulse inhibition
Avpr1atm1Gzt Avpr1atm1Gzt/Avpr1atm1Gzt
involves: 129/Sv * C57BL/6J		 MGI:1859216  MP:0001596 hypotension PMID: 16682631 
Avpr1atm1Sbhu Avpr1atm1Sbhu/Avpr1atm1Sbhu
involves: C57BL/6		 MGI:1859216  MP:0008167 increased B-1a cell number PMID: 12576226 
Avpr1atm1Sbhu Avpr1atm1Sbhu/Avpr1atm1Sbhu
involves: C57BL/6		 MGI:1859216  MP:0008500 increased IgG2a level PMID: 12576226 
Avpr1atm1Gzt Avpr1atm1Gzt/Avpr1atm1Gzt
involves: 129/Sv * C57BL/6J		 MGI:1859216  MP:0001633 poor circulation PMID: 16682631 
Biologically Significant Variants
Four SNPs in the promotor region of the V1A receptor gene have been found in human platelets.
Type:  Single nucleotide polymorphisms.
Species:  Human
References:  29
General Comments
V1A vasopressin receptors modulate the vasopressor actions of arginine vasopressin (AVP). They have been shown to be present in many tissues including the brain. They mediate vascular smooth muscle cell contraction and proliferation, liver glycogenolysis, platelet aggregation, aldosterone secretion by the adrenals, and subserve neurotransmitter-like actions of AVP in the central nervous system.

Overexpression of the V1A receptor has been found in adrenocorticotropin-independent macromodular adrenal hyperplasia [43,76]. Vasopressin V1A receptors form homodimers in vitro and may heterodimerise with vasopressin V2 and oxytocin receptors [68-69].

The pattern of V1A receptor expression in the brain may be associated with species-typical social behaviours (e.g., affiliative behaviour) in rodents [38,80]. Polymorphisms in the promoter region of the V1A receptor gene have been associated with decision making in a dictator game [36] and creative dance performance [4] in humans. An association between polymorphisms in the V1A receptor gene and autism has been found in some [79] but not all [35] studies.

REFERENCES

Show »

1. Akerlund, M., Bossmar, T., Brouard, R., Kostrzewska, A., Laudanski, T., Lemancewicz, A., Serradeil-Le Gal, C. and Steinwall, M. (1999) Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women. Br J Obstet Gynaecol, 106: 1047-1053. [PMID:10519430]

2. Andres, M., Trueba, M. and Guillon, G. (2002) Pharmacological characterization of F-180: a selective human V1a vasopressin receptor agonist of higly affinity. Br J Pharmacol, 135: 1828-1836. [PMID:11934825]

3. Aoyagi, T., Birumachi, J., Hiroyama, M., Fujiwara, Y., Sanbe, A., Yamauchi, J. and Tanoue, A. (2007) Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology, 148: 2075-2084. [PMID:17303660]

4. Bachner-Melman, R., Dina, C., Zohar, A. H., Constantini, N., Lerer, E., Hoch, S., Sella, S., Nemanov, L., Gritsenko, I., Lichtenberg, P., Granot, R. and Ebstein, R. P. (2005) AVPR1a and SLC6A4 gene polymorphisms are associated with creative dance performance. PLoS Genet, 1: e42-e42. [PMID:16205790]

5. Bielsky, I. F., Hu, S. B. and Young, L. J. (2005) Sexual dimorphism in the vasopressin system: lack of an altered behavioral phenotype in female V1a receptor knockout mice. Behav Brain Res, 164: 132-136. [PMID:16046007]

6. Bielsky, I. F., Hu, S. B., Ren, X., Terwilliger, E. F. and Young, L. J. (2005) The V1a vasopressin receptor is necessary and sufficient for normal social recognition: a gene replacement study. Neuron, 47: 503-513. [PMID:16102534]

7. Bielsky, I. F., Hu, S. B., Szegda, K. L., Westphal, H. and Young, L. J. (2004) Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology, 29: 483-493. [PMID:14647484]

8. Birumachi, J., Hiroyama, M., Fujiwara, Y., Aoyagi, T., Sanbe, A. and Tanoue, A. (2007) Impaired arginine-vasopressin-induced aldosterone release from adrenal gland cells in mice lacking the vasopressin V1A receptor. Eur J Pharmacol, 566: 226-230. [PMID:17449028]

9. Breton, C., Chellil, H., Kabbaj-Benmansour, M., Carnazzi, E., Seyer, R., Phalipou, S., Morin, D., Durroux, T., Zingg, H. H., Barberis, C. and Mouillac, B. (2001) Direct identification of human oxytocin receptor-binding domains using a photoactivatable cyclic peptide antagonist: comparison with the human V1a vasopressin receptor. J Biol Chem, 276: 26931-26941. [PMID:11337500]

10. Briley, E. M., Lolait, S. J., Axelrod, J. and Felder, C. C. (1994) The cloned vasopressin V1a receptor stimulates phospholipase A2, phospholipase C, and phospholipase D through activation of receptor-operated calcium channels. Neuropeptides, 27: 63-74. [PMID:7969820]

11. Brouard, R., Laporte, V., Serradeil Le Gal, C., Pignol, R., Jang, H., Donat, F., Lockwood, G., Fournie, D. and Dreux, F. (1998) Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers. Adv Exp Med Biol, 449: 455-465. [PMID:10026839]

12. Caldwell, H. K., Stewart, J., Wiedholz, L. M., Millstein, R. A., Iacangelo, A., Holmes, A., Young, W. S. and Wersinger, S. R. (2006) The acute intoxicating effects of ethanol are not dependent on the vasopressin 1a or 1b receptors. Neuropeptides, 40: 325-337. [PMID:17049983]

13. Chandrashekhar, Y., Prahash, A. J., Sen, S., Gupta, S., Roy, S. and Anand, I. S. (2003) The role of arginine vasopressin and its receptors in the normal and failing rat heart. J Mol Cell Cardiol, 35: 495-504. [PMID:12738231]

14. Chen, Y. L., Shepherd, C., Spinelli, W. and Lai, F. M. (1999) Oxytocin and vasopressin constrict rat isolated uterine resistance arteries by activating vasopressin V1A receptors. Eur J Pharmacol, 376: 45-51. [PMID:10440088]

15. Cheng, L. L., Stoev, S., Manning, M., Derick, S., Pena, A., Mimoun, M. B. and Guillon, G. (2004) Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem, 47: 2375-2388. [PMID:15084136]

16. Chini, B., Mouillac, B., Ala, Y., Balestre, M. N., Trumpp-Kallmeyer, S., Hoflack, J., Elands, J., Hibert, M., Manning, M., Jard, S. et al.. (1995) Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. The EMBO Journal., 14: 2176-2182. [PMID:7774575]

17. Cirillo, R., Gillio Tos, E., Schwarz, M. K., Quattropani, A., Scheer, A., Missotten, M., Dorbais, J., Nichols, A., Borrelli, F., Giachetti, C., Golzio, L., Marinelli, P., Thomas, R. J., Chevillard, C., Laurent, F., Portet, K., Barberis, C. and Chollet, A. (2003) Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor. J Pharmacol Exp Ther, 306: 253-261. [PMID:12660315]

18. Clerget, M. S., Elalouf, J. M. and Germain, G. (1997) Quantitative reverse transcription and polymerase chain reaction analysis of oxytocin and vasopressin receptor mRNAs in the rat uterus near parturition. Mol Cell Endocrinol, 136: 79-89. [PMID:9510070]

19. Cotte, N., Balestre, M. N., Aumelas, A., Mahe, E., Phalipou, S., Morin, D., Hibert, M., Manning, M., Durroux, T., Barberis, C. and Mouillac, B. (2000) Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding. Eur J Biochem, 267: 4253-4263. [PMID:10866830]

20. Cotte, N., Balestre, M. N., Phalipou, S., Hibert, M., Manning, M., Barberis, C. and Mouillac, B. (1998) Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor. J Biol Chem, 273: 29462-29468. [PMID:9792651]

21. Derick, S., Cheng, L. L., Stoev, S., Voirol, M. J., Ben Mimoun, M., Andres, M., Gaillard, R., Guillon, G. and Manning, M. (2002) [1-Deamino-4-Cyclohexylalanine]Arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors. Endocrinology., 143: 4655-4664. [PMID:12446593]

22. Egashira, N., Tanoue, A., Higashihara, F., Mishima, K., Fukue, Y., Takano, Y., Tsujimoto, G., Iwasaki, K. and Fujiwara, M. (2004) V1a receptor knockout mice exhibit impairment of spatial memory in an eight-arm radial maze. Neurosci Lett, 356: 195-198. [PMID:15036628]

23. Egashira, N., Tanoue, A., Matsuda, T., Koushi, E., Harada, S., Takano, Y., Tsujimoto, G., Mishima, K., Iwasaki, K. and Fujiwara, M. (2007) Impaired social interaction and reduced anxiety-related behavior in vasopressin V1a receptor knockout mice. Behav Brain Res, 178: 123-127. [PMID:17227684]

24. Grazzini, E., Boccara, G., Joubert, D., Trueba, M., Durroux, T., Guillon, G., Gallo-Payet, N., Chouinard, L., Payet, M. D. and Serradeil Le Gal, C. (1998) Vasopressin regulates adrenal functions by acting through different vasopressin receptor subtypes. Adv Exp Med Biol, 449: 325-334. [PMID:10026821]

25. Grazzini, E., Breton, C., Derick, S., Andres, M., Raufaste, D., Rickwaert, F., Boccara, G., Colson, P., Guérineau, N. C., Serradeil-Le Gal, C. and Guillon, G. (1999) Vasopressin receptors in human adrenal medulla and pheochromocytoma. J Clin Endocrinol Metab, 84: 2195-2203. [PMID:10372731]

26. Griffante, C., Green, A., Curcuruto, O., Haslam, C. P., Dickinson, B. A. and Arban, R. (2005) Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist. Br J Pharmacol, 146: 744-751. [PMID:16158071]

27. Guillon, G., Grazzini, E., Andrez, M., Breton, C., Trueba, M., Serradeil-LeGal, C., Boccara, G., Derick, S., Chouinard, L. and Gallo-Payet, N. (1998) Vasopressin : a potent autocrine/paracrine regulator of mammal adrenal functions. Endocr Res, 24: 703-710. [PMID:9888562]

28. Gunnet, J. W., Matthews, J. M., Maryanoff, B. E., de Garavilla, L., Andrade-Gordon, P., Damiano, B., Hageman, W., Look, R., Stahle, P., Streeter, A. J., Wines, P. G. and Demarest, K. T. (2006) Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist. Clin Exp Pharmacol Physiol, 33: 320-326. [PMID:16620295]

29. Hasan, K. N., Shoji, M., Tsutaya, S., Kudo, R., Matsuda, E., Saito, J., Kimura, T. and Yasujima, M. (2006) Study of V1a vasopressin receptor gene single nucleotide polymorphisms in platelet vasopressin responsiveness. J Clin Lab Anal, 20: 87-92. [PMID:16721832]

30. Hirasawa, A., Hashimoto, K. and Tsujimoto, G. (1994) Distribution and developmental change of vasopressin V1A and V2 receptor mRNA in rats. Eur J Pharmacol, 267: 71-75. [PMID:8206132]

31. Hiroyama, M., Aoyagi, T., Fujiwara, Y., Birumachi, J., Shigematsu, Y., Kiwaki, K., Tasaki, R., Endo, F. and Tanoue, A. (2007) Hypermetabolism of fat in V1a vasopressin receptor knockout mice. Mol Endocrinol, 21: 247-258. [PMID:17021052]

32. Hiroyama, M., Aoyagi, T., Fujiwara, Y., Oshikawa, S., Sanbe, A., Endo, F. and Tanoue, A. (2007) Hyperammonemia in V1a vasopressin receptor knockout mice caused by the promoted proteolysis and reduced intrahepatic blood volume. J Physiol, 581: 1183-1192. [PMID:17379633]

33. Hiroyama, M., Wang, S., Aoyagi, T., Oikawa, R., Sanbe, A., Takeo, S. and Tanoue, A. (2007) Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice. Eur J Pharmacol, 559: 89-97. [PMID:17275806]

34. Kikuchi, S., Tanoue, A., Goda, N., Matsuo, N. and Tsujimoto, G. (1999) Structure and sequence of the mouse V1a and V1b vasopressin receptor genes. Jpn J Pharmacol., 81: 388-392. [PMID:10669045]

35. Kim, S. J., Young, L. J., Gonen, D., Veenstra-VanderWeele, J., Courchesne, R., Courchesne, E., Lord, C., Leventhal, B. L., Cook, E. H. and Insel, T. R. (2002) Transmission disequilibrium testing of arginine vasopressin receptor 1A (AVPR1A) polymorphisms in autism. Mol Psychiatry, 7: 503-507. [PMID:12082568]

36. Knafo, A., Israel, S., Darvasi, A., Bachner-Melman, R., Uzefovsky, F., Cohen, L., Feldman, E., Lerer, E., Laiba, E., Raz, Y., Nemanov, L., Gritsenko, I., Dina, C., Agam, G., Dean, B., Bornstein, G. and Ebstein, R. P. (2007) Individual differences in allocation of funds in the dictator game associated with length of the arginine vasopressin 1a receptor RS3 promoter region and correlation between RS3 length and hippocampal mRNA. Genes Brain Behav, : -. [PMID:17696996]

37. Koshimizu, T. A., Nasa, Y., Tanoue, A., Oikawa, R., Kawahara, Y., Kiyono, Y., Adachi, T., Tanaka, T., Kuwaki, T., Mori, T., Takeo, S., Okamura, H. and Tsujimoto, G. (2006) V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci U S A, 103: 7807-7812. [PMID:16682631]

38. Lim, M. M., Wang, Z., Olazábal, D. E., Ren, X., Terwilliger, E. F. and Young, L. J. (2004) Enhanced partner preference in a promiscuous species by manipulating the expression of a single gene. Nature, 429: 754-757. [PMID:15201909]

39. Loichot, C., Krieger, J. P., De Jong, W., Nisato, D., Imbs, J. L. and Barthelmebs, M. (2001) High concentrations of oxytocin cause vasoconstriction by activating vasopressin V1A receptors in the isolated perfused rat kidney. Naunyn Schmiedebergs Arch Pharmacol, 363: 369-375. [PMID:11330329]

40. Manning, M., Cheng, L. L., Stoev, S., Wo, N. C., Chan, W. Y., Szeto, H. H., Durroux, T., Mouillac, B. and Barberis, C. (2005) Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban. J Pept Sci, 11: 593-608. [PMID:15880385]

41. Meidan, R. and Hsueh, A. J. (1985) Identification and characterization of arginine vasopressin receptors in the rat testis. Endocrinology, 116: 416-423. [PMID:2981073]

42. Morel, A., O'Carroll, A. M., Brownstein, M. J. and Lolait, S. J. (1992) Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature., 356: 523-526. [PMID:1560825]

43. Mune, T., Murase, H., Yamakita, N., Fukuda, T., Murayama, M., Miura, A., Suwa, T., Hanafusa, J., Daido, H., Morita, H. and Yasuda, K. (2002) Eutopic overexpression of vasopressin v1a receptor in adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab, 87: 5706-5713. [PMID:12466375]

44. Murasawa, S., Matsubara, H., Kizima, K., Maruyama, K., Mori, Y. and Inada, M. (1995) Glucocorticoids regulate V1a vasopressin receptor expression by increasing mRNA stability in vascular smooth muscle cells. Hypertension, 26: 665-669. [PMID:7558228]

45. Naitoh, M., Burrell, L. M., Risvanis, J., Aldred, K. L., Rockell, M. D., Johnston, C. I. and Phillips, P. A. (1997) Modulation of genetic hypertension by short-term AVP V1A or V2 receptor antagonism in young SHR. Am J Physiol, 272: F229-F234. [PMID:9124400]

46. Nakamura, S., Yamamura, Y., Itoh, S., Hirano, T., Tsujimae, K., Aoyama, M., Kondo, K., Ogawa, H., Shinohara, T., Kan, K., Tanada, Y., Teramoto, S., Sumida, T., Nakayama, S., Sekiguchi, K., Kambe, T., Tsujimoto, G., Mori, T. and Tominaga, M. (2000) Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes. Br J Pharmacol, 129: 1700-1706. [PMID:10780976]

47. Oikawa, R., Nasa, Y., Ishii, R., Kuwaki, T., Tanoue, A., Tsujimoto, G. and Takeo, S. (2007) Vasopressin V1A receptor enhances baroreflex via the central component of the reflex arc. Eur J Pharmacol, 558: 144-150. [PMID:17224142]

48. Ostrowski, N. L., Lolait, S. J. and Young, W. S. (1994) Cellular localization of vasopressin V1a receptor messenger ribonucleic acid in adult male rat brain, pineal, and brain vasculature. Endocrinology, 135: 1511-1528. [PMID:7925112]

49. Ostrowski, N. L., Young, W. S., Knepper, M. A. and Lolait, S. J. (1993) Expression of vasopressin V1a and V2 receptor messenger ribonucleic acid in the liver and kidney of embryonic, developing, and adult rats. Endocrinology, 133: 1849-1859. [PMID:8404628]

50. Pena, A., Murat, B., Trueba, M., Ventura, M. A., Wo, N. C., Szeto, H. H., Cheng, L. L., Stoev, S., Guillon, G. and Manning, M. (2007) Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8. J Med Chem, 50: 835-847. [PMID:17300166]

51. Phalipou, S., Cotte, N., Carnazzi, E., Seyer, R., Mahe, E., Jard, S. and Barberis, C. (1997) Mapping peptide binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem, 272: 26536-26544. [PMID:9334232]

52. Quattropani, A., Dorbais, J., Covini, D., Pittet, P. A., Colovray, V., Thomas, R. J., Coxhead, R., Halazy, S., Scheer, A., Missotten, M., Ayala, G., Bradshaw, C., De Raemy-Schenk, A. M., Nichols, A., Cirillo, R., Tos, E. G., Giachetti, C., Golzio, L., Marinelli, P., Church, D. J., Barberis, C., Chollet, A. and Schwarz, M. K. (2005) Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists. J Med Chem, 48: 7882-7905. [PMID:16302826]

53. Saito, M., Tahara, A. and Sugimoto, T. (1997) 1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor. Biochem Pharmacol, 53: 1711-1717. [PMID:9264324]

54. Schöneberg, T., Kostenis, E., Liu, J., Gudermann, T. and Wess, J. (1998) Molecular aspects of vasopressin receptor function. Adv Exp Med Biol, 449: 347-358. [PMID:10026824]

55. Serradeil-Le Gal, C., Raufaste, D., Double-Cazanave, E., Guillon, G., Garcia, C., Pascal, M. and Maffrand, J. P. (2000) Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463. Kidney Int, 58: 1613-1622. [PMID:11012895]

56. Serradeil-Le Gal, C., Valette, G., Foulon, L., Germain, G., Advenier, C., Naline, E., Bardou, M., Martinolle, J-P., Pouzet, B., Raufaste, D., Garcia, C., Double-Cazenave, E., Pauly, M., Pascal, M., Barbier, A., Scatton, B., Maffrand, J-P. and Le Fur, G. (2004) SSR126768A (4-Chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamidine, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor. J Pharmacol Exp Therap, 309: 414-424. [PMID:14722330]

57. Serradeil-Le Gal, C., Wagnon, J., Garcia, C., Lacour, C., Guiraudou, P., Christophe, B., Villanova, G., Nisato, D., Maffrand, J. P., Le Fur, G. et al.. (1993) Biochemical and pharmacological properties of SR49059, a new potent nonpeptide antagonist of rat and human vasopressin V1a receptor. J Clin Invest, 92: 224-231. [PMID:8392086]

58. Serradeil-Le Gal, C., Wagnon, J., Simiand, J., Griebel, G., Lacour, C., Guillon, G., Barberis, C., Brossard, G., Soubrie, P., Nisato, D., Pascal, M., Pruss, R., Scatton, B., Maffrand, J. P. and Le Fur, G. (2002) Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther, 300: 1122-1130. [PMID:11861823]

59. Shi, W., Cui, N., Shi, Y., Zhang, X., Yang, Y. and Jiang, C. (2007) Arginine vasopressin inhibits Kir6.1/SUR2B channel and constricts the mesenteric artery via V1a receptor and protein kinase C. Am J Physiol Regul Integr Comp Physiol, 293: R191-R199. [PMID:17428891]

60. Szot, P., Bale, T. L. and Dorsa, D. M. (1994) Distribution of messenger RNA for the vasopressin V1a receptor in the CNS of male and female rats. Brain Res Mol Brain Res, 24: 1-10. [PMID:7968346]

61. Tachikawa, K., Yokoi, H., Nagasaki, H., Arima, H., Murase, T., Sugimura, Y., Miura, Y., Hirabayashi, M. and Oiso, Y. (2003) Altered cardiovascular regulation in arginine vasopressin-overexpressing transgenic rat. Am J Physiol Endocrinol Metab, 285: E1161-E1166. [PMID:12915399]

62. Tahara, A., Saito, M., Sugimoto, J., Tomura, Y., Wada, K. I., Kusayama, T., Tsukada, J., Ishii, I., Yatsu, T., Uchida, W. and Tanaka, A. (1998) Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in chinese hamster ovary cells. Br J Pharmacol, 125: 1463-1470. [PMID:9884074]

63. Tahara, A., Saito, M., Sugimoto, T., Tomura, Y., Wada, K., Kusayama, T., Tsukada, J., Ishii, N., Yatsu, T., Uchida, W. and Tanaka, A. (1998) Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol, 357: 63-69. [PMID:9459574]

64. Tahara, A., Saito, M., Sugimoto, T., Tomura, Y., Wada, K., Kusayama, T., Tsukada, J., Ishii, N., Yatsu, T., Uchida, W. and Tanaka, A. (1999) AVP-induced mitogenic responses of Chinese hamster ovary cells expressing human V1A or V1B receptors. Pflugers Arch, 437: 219-226. [PMID:9929562]

65. Tahara, A., Tomura, Y., Wada, K., Kusayama, T., Tsukada, J., Ishii, N., Yatsu, T., Uchida, W. and Tanaka, A. (1998) Characterization of vasopressin receptor in rat lung. Neuropeptides, 32: 281-286. [PMID:10189064]

66. Tahara, A., Tsukada, J., Tomura, Y., Kusayama, T., Wada, K., Ishii, N., Taniguchi, N., Suzuki, T., Yatsu, T., Uchida, W. and Shibasaki, M. (2005) Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors. Pharmacol Res, 51: 275-281. [PMID:15661579]

67. Terada, Y., Tomita, K., Nonoguchi, H., Yang, T. and Marumo, F. (1993) Different localization and regulation of two types of vasopressin receptor messenger RNA in microdissected rat nephron segments using reverse transcription polymerase chain reaction. J Clin Invest, 92: 2339-2345. [PMID:8227349]

68. Terrillon, S., Barberis, C. and Bouvier, M. (2004) Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patterns. Proc Natl Acad Sci U S A, 101: 1548-1553. [PMID:14757828]

69. Terrillon, S., Durroux, T., Mouillac, B., Breit, A., Ayoub, M. A., Taulan, M., Jockers, R., Barberis, C. and Bouvier, M. (2003) Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol Endocrinol, 17: 677-691. [PMID:12554793]

70. Thibonnier, M., Auzan, C., Madhun, Z., Wilkins, P., Berti-Mattera, L. and Clauser, E. (1994) Molecular cloning, sequencing, and functional expression of a cDNA encoding thehuman V1a vasopressin receptor. J Biol Chem, 269: 3304-3310. [PMID:8106369]

71. Thibonnier, M., Graves, M. K., Wagner, M. S., Auzan, C., Clauser, E. and Willard, H. F. (1996) Structure, sequence, expression, and chromosomal localization of the human V1a vasopressin receptor gene. Genomics, 31: 327-334. [PMID:8838314]

72. Thibonnier, M., Preston, J. A., Dulin, N., Wilkins, P. L., Berti-Matera, L. N. and Mattera, R. (1997) The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology., 138: 4109-4122. [PMID:9322919]

73. Thornton, S., Baldwin, P. J., Harris, P. A., Harding, F., Davison, J. M., Baylis, P. H., Timmons, P. M. and Wathes, D. C. (2002) The role of arginine vasopressin in human labour: functional studies, fetal production and localisation of V1a receptor mRNA. BJOG, 109: 57-62. [PMID:11843375]

74. Trejter, M., Carraro, G., Rucinski, M., Hochol, A., Rebuffat, P., Nussdorfer, G. G. and Malendowicz, L. K. (2005) Arginin-vasopressin regulates proliferative activity of the regenerating rat adrenal cortex. Int J Mol Med, 15: 993-997. [PMID:15870905]

75. Tsukada, J., Tahara, A., Tomura, Y., Wada, Ki., Kusayama, T., Ishii, N., Yatsu, T., Uchida, W., Taniguchi, N. and Tanaka, A. (2001) Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells. Br J Pharmacol., 133: 746-754. [PMID:11429400]

76. Vezzosi, D., Cartier, D., Régnier, C., Otal, P., Bennet, A., Parmentier, F., Plantavid, M., Lacroix, A., Lefebvre, H. and Caron, P. (2007) Familial adrenocorticotropin-independent macronodular adrenal hyperplasia with aberrant serotonin and vasopressin adrenal receptors. Eur J Endocrinol, 156: 21-31. [PMID:17218722]

77. Wersinger, S. R., Caldwell, H. K., Martinez, L., Gold, P., Hu, S. B. and Young, W. S. (2007) Vasopressin 1a receptor knockout mice have a subtle olfactory deficit but normal aggression. Genes Brain Behav, 6: 540-551. [PMID:17083331]

78. Yamamura, Y., Nakamura, S., Itoh, S., Hirano, T., Onogawa, T., Yamashita, T., Yamada, Y., Tsujimae, K., Aoyama, M., Kotosai, K., Ogawa, H., Yamashita, H., Kondo, K., Tominaga, M., Tsujimoto, G. and Mori, T. (1998) OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther, 287: 860-867. [PMID:9864265]

79. Yirmiya, N., Rosenberg, C., Levi, S., Salomon, S., Shulman, C., Nemanov, L., Dina, C. and Ebstein, R. P. (2006) Association between the arginine vasopressin 1a receptor (AVPR1a) gene and autism in a family-based study: mediation by socialization skills. Mol Psychiatry, 11: 488-494. [PMID:16520824]

80. Young, L. J., Nilsen, R., Waymire, K. G., MacGregor, G. R. and Insel, T. R. (1999) Increased affiliative response to vasopressin in mice expressing the V1a receptor from a monogamous vole. Nature, 400: 766-768. [PMID:10466725]

To cite this database page, please use the following:

Daniel Bichet, Michel Bouvier, Bice Chini, Gerald Gimpl, Gilles Guillon, Tadashi Kimura, Mark Knepper, Stephen Lolait, Maurice Manning, Bernard Mouillac, Claudine Serradeil-Le Gal, Melvyn Soloff, Joseph G. Verbalis, Mark Wheatley, Hans H. Zingg.
Vasopressin and oxytocin receptors: V1A receptor. Last modified on 15/02/2013. Accessed on 18/05/2013. IUPHAR database (IUPHAR-DB), http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=366.


Contact us | Print | Back to top | Help